Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Intellectual Property Gmbh

Piramal Imaging Sa

Abbott Gmbh & Co Kg

Georg Kettschau

Philip Lienau

Hans Briem

Ingo Hartung

Ulrich Klar

Karl-Heinz Thierauch

Detlev Sülzle

Lars Wortmann

Keith Graham

Ulf Boemer

Ulf Bömer

Stuart Ince

Dirk Kosemund

Wolfgang Schwede

Knut Eis

Anne Mengel

Ulrich Bothe

Andrea Hägebarth

Kirstin Petersen

Martin Krueger

Antonius Ter Laak

Florian Puehler

Lutz Lehmann

Florian Pühler

Ulrich Luecking

Liliane Unger

Andreas Haupt

Thomas Zierke

Heribert Schmitt-Willich

Ulrich Lücking

Hervé Geneste

Antje Margret Wengner

Duy Nguyen

Thomas Brumby

Martin Kruger

Dorothea Starck

Hans-Jurgen Teschendorf

Olaf Prien

Timo Stellfeld

Mathias Berndt

Hermann Kuenzer

Julien Lefranc

Tobias Heinrich

Jorma Haβfeld

Arne Von Bonin

Hans-Jörg Treiber

Karl H Thierauch

Nicole Schmidt

Christer Halldin

Anja Richter

Andre Müller

Martin Krüger

Andrea Thiele

Balazs Gulyas

Sangram Nag

Oliver Von Ahsen

Kai Blumbach

Martina Schaefer

Manfred Husemann

Anja Giese

Florian Püehler

Andrea Varrone

Antonius M Laak Ter

Krolikiewicz Konrad

Dietmar Schöbel

Stephan Siegel

Ulf BÖMER

Balazs GULYÁS

Antonius M Ter Laak

The present invention relates to substituted pyrazolopyridinamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, inflammatory disease and disease associated with inflammatory pain, as a sole agent or in combination with other active ingredients.

Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors

The present invention relates to substituted thiazolopyrimidine compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

Substituted thiazolopyrimidines

The present invention relates to substituted pyrazolopyrimidinylamino-indazole compounds of formula I, below, as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients wherein R, R, R, and Rare defined herein.

Substituted pyrazolopyrimidinylamino-indazoles

The present invention relates to substituted thienopyrimidine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Thienopyrimidines

The present invention relates to substituted pyrrolopyrimidinylamino-benzothiazolone compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors

This invention relates to novel compounds suitable as precursors for the preparation of certainF labelled positron emission tomography (PET) tracers. Furthermore the invention relates to the preparation of such precursor molecules and to the preparation of PET tracers byF labelling of such precursors.

Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system

The present invention relates to substituted benzothienopyrimidine compounds of general formula I: in which R, R, R, R, and Rare as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Substituted benzothienopyrimidines

This invention relates to novel compounds suitable for labeling byF and to the correspondingF labeled compounds themselves,F-fluorinated analogs thereof and their use as reference standards, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by Positron Emission Tomography (PET).

Radiolabeled amino acids for diagnostic imaging

The invention relates to alkynylpyrimidines according to the general formula (I): in which A, R, R, R, R, R, and Rare as defined in the claims, and salts, N-oxides, metabolites, solvates, tautomers and prodrugs thereof, to pharmaceutical compositions comprising said alkynylpyrimidines, to methods of preparing said alkynylpyrimidines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 and VEGFR2 signalling.

Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

The invention relates to alkynylaryl compounds according to the general formula (I) in which A, B, D, E, R, R, R, R, Rand q are as defined in the claims, and salts, N-oxides, solvates and prodrugs thereof, to pharmaceutical compositions comprising said alkynylaryl compounds, to methods of preparing said alkynylaryl compounds, to intermediate compounds useful in said methods, to uses of said intermediate compounds in the preparation of said alkynylaryl compounds, as well as to uses of said alkynylaryl compounds for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth. 

Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

The invention relates to substituted sulphoximines according to the general formula (I): in which A, E, G, X, R, R, R, R, R, R, R, R, m, p, q, are given in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted sulphoximines, to methods of preparing said substituted sulphoximines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

Substituted sulphoximines as TIE2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

The invention relates to substituted pyrazolopyridines according to the general formula (I): in which A, B, D, E, R, R, R, R, R, Rand q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted pyrazolopyridine compounds, to methods of preparing said substituted pyrazolopyridines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

The invention relates to pyrazolopyridines according to the general formula (I): and salts thereof, to pharmaceutical compositions comprising said pyrazolopyridines and to a method of preparing said pyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling.

Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same

The invention relates to substituted aminopyrazolopyridines according to the general formula (I): in which A, B, D, E, R, R, R, R, R, Rand q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted aminopyrazolopyridines, to methods of preparing said substituted aminopyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

The invention relates to sulfoximine-substituted pyrimidines of the general formula I processes for the preparation thereof and their use as drugs.

Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs

Growing community of inventors

Berlin, Germany

Georg Kettschau